The abundance of PD-L1 in TME could predict therapeutic response to ICIs in multiple cancers, such as melanoma (Caroline et al., 2015) and cancer in lung (Borghaei et al., 2015) and bladder (Rosenberg et al., 2016). The gene discussed is CD274; the disease is melanoma.